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Diversion colitis (DC) is an inflammatory disease that develops in segments with fecal di-
version. Sucralfate (SCF) complex, which consists of sucrose octasulfate and polyaluminum 
hydroxide, has been demonstrated to be effective in the treatment of different forms of 
colitis. However, until now, the effects of SCF have not been evaluated in DC.
Objective: to evaluate whether the use of enemas containing SFC improves histological find-
ings in experimental DC.
Methods: Thirty-six rats underwent right colon bypass procedure through the creation of a 
proximal colostomy and a distal mucous fistula. The animals were divided into two groups 
according to the euthanization procedure to be performed two to four weeks after sur-
gery. Each experimental group was divided into three subgroups of six animals, which were 
submitted to daily application of enemas containing saline solution 0.9% or SCF at con-
centrations of 1.0 g/kg/day or 2.0 g/kg/day, respectively. The diagnosis of DC in segments 
with fecal diversion was established by histopathological study considering the following 
variables: epithelial loss, formation of crypt abscesses, the population of goblet cells, in-
flammatory infiltrate and presence of fibrosis. For statistical analysis, the nonparametric 
Mann-Whitney and Kruskal-Wallis tests were used, with a significance level of 5% (p <0.05). 
Results: It was observed that the daily application of SCF enemas decreased epithelial loss, 
formation of colon crypt abscesses, inflammatory infiltrate and tissue fibrosis (p <0.05), un-
related to time of intervention. The intervention with SCF preserves the goblet cell popula-
tion. The effects of the substance on the preservation of colonic epithelium; the decrease 
in the inflammatory process and subsequent abscess formation in the colon crypts are 
associated with the concentration used, whereas tissue fibrosis decrease is associated with 
the concentration and time of intervention.
Conclusion: Preventive application of SCF enemas reduces the inflammatory process in the 
colon with fecal diversion
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Avaliação dos efeitos da aplicação de enemas com sucralfato em modelo 
experimental de colite de exclusão
A colite de exclusão (CE) é uma doença inflamatória que se desenvolve em segmentos 
desprovidos de trânsito fecal. O sucralfato (SCF) complexo formado pelo octossulfato de 
sacarose e hidróxido de polialumínio vem se demonstrando eficaz para o tratamento de 
diferentes formas de colite, porém, até a presente data, os efeitos do SCF ainda não foram 
avaliados na CE. 
Objetivo: avaliar se a aplicação de clisteres contendo SFC melhora as alterações histológicas 
encontradas em modelo experimental de CE. 
Métodos: trinta e seis ratos foram submetidos à derivação do trânsito no cólon direito pela 
confecção de colostomia proximal e fístula mucosa distal. Os animais foram divididos em 
dois grupos experimentais de acordo com o sacrifício ser realizado após duas ou quatro 
semanas do procedimento cirúrgico. Cada grupo experimental foi dividido em três subgru-
pos de seis animais segundo terem sidos submetidos à aplicação diária com enemas con-
tendo solução fisiológica a 0,9% ou SCF nas concentrações de 1,0g/kg/dia ou 2,0 g/kg/dia. O 
diagnóstico de CE nos segmentos sem trânsito foi estabelecido por estudo histopatológico 
considerando-se as seguintes variáveis: perda epitelial, formação de abscessos nas criptas, 
população de células caliciformes, infiltrado inflamatório e a presença de fibrose. Para aná-
lise estatística adotou-se os testes não paramétricos de Mann-Withney e Kruskal-Wallis 
estabelecendo-se para ambos, nível de significância de 5% (p < 0,05). 
Resultados: verificou-se que a aplicação diária de enemas com SCF diminui a perda epite-
lial, a formação de abscessos nas criptas cólicas, o infiltrado inflamatório e a presença de 
fibrose tecidual (p < 0,05), não relacionada ao tempo de intervenção. A intervenção com SCF 
preserva a população de células caliciformes. Os efeitos da substância na preservação do 
epitélio cólico, na redução do processo inflamatório e consequente formação de abscessos 
nas criptas cólicas encontram-se relacionado à concentração utilizada, enquanto a redução 
da fibrose tecidual a concentração e ao tempo de intervenção. 
Conclusão: a aplicação preventiva de enemas com SCF reduz o processo inflamatório em 
segmentos cólicos desprovidos de transito intestinal.
Introduction
Sucralfate (SCF) is the salt formed by the association of disac-
charide sucrose octasulfate and poly-aluminum hydroxide.1 
This substance is a cytoprotective complex, which was ini-
tially used to prevent or treat several diseases of the upper di-
gestive tract, mainly represented by gastroesophageal reflux 
disease (GERD), gastritis, peptic ulcers, stress ulcers and acute 
gastric mucosal lesions.2 Subsequent studies demonstrated 
that SCF had beneficial effects on skin and mucosal wound 
healing,  and being successfully used for the treatment of 
lesions found in varicose ulcers, aphthous stomatitis, oral 
and genital ulcers in Behcet’s disease, peristomal dermatitis, 
burns and post-hemorrhoidectomy or fistulectomy surgical 
wounds.3-9   
The therapeutic effects of the topical use of SCF on skin 
and mucosal lesions are related to the property that the 
formed complex has to adhere strongly to the raw surface of 
epithelial ulcers, making it difficult to remove the gelatinous 
layer that forms on the lesion. The adhesive capacity over the 
raw surface of the wounds seems to be the main mechanism 
of action of the drug. However, more recently it was shown 
that the molecule possesses other properties, such as stimu-
lating the formation of mucus and increasing the production 
of prostaglandins and epithelial growth factor (EGF).10 The 
topical use of SCF has also antioxidant activity and is capable 
of reducing the formation of oxygen-free radicals (reactive 
oxygen species or ROS) produced by leukocytes present in the 
inflamed tissue. This antioxidant action prevents the peroxi-
dation of cell membrane lipids and, therefore, prevents tissue 
damage.11  
Kochhar et al. were the first to demonstrate the short-term 
effectiveness of the application of enemas containing SCF for 
the control of rectal bleeding due to radiation proctitis.12 The 
authors showed that the use of  enemas containing a 10% SCF 
suspension inhibited rectal bleeding in most of the patients 
with radiation proctitis of moderate or severe intensity. From 
then on, a sequence of well-conducted studies confirmed the 
beneficial therapeutic effects of the drug in clinical, endo-
scopic and histological improvement in patients with radia-
tion proctitis, as well as in other forms of inflammatory bowel 
disease (IBD) accompanied by the formation of ulcers in the 
colonic mucosa, such as ulcerative colitis (UC) and solitary 
rectal ulcer.12-18  
Glotzer et al. in 1981, described for the first time the de-
velopment of aphthous ulcers, similar to those found in the 
UC, in segments of the colonic mucosa with fecal diversion in 
patients who had no history of IBD.19 The authors called this 
new form of IBD “diversion colitis” (DC). It has been shown 
that the DC appears as a result of the deficiency in the sup-
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ply of intraluminal short-chain fatty acids (SCFA) to epithelial 
cells of the colonic mucosa, caused by bowel bypass. Recent 
studies suggest that epithelial injury in DC is caused by the 
increased production of ROS by the epithelial cells of the co-
lonic mucosa itself, along with changes in its metabolism as 
a result of a deficiency in the supply of its main energy sub-
strate represented by the SCFA.20-23 
Different therapeutic strategies have been used in the 
treatment of DC. The restoration of SCFA supply either by 
reconstitution of the fecal stream or by applying nutritional 
solutions rich in SCFA is able to ameliorate epithelial lesions. 
Recent studies have shown that the use of enemas containing 
substances with antioxidant activity, such as 5-ASA and N-
acetylcysteine, as they decrease the levels of oxidative stress 
in the tissue, they may also improve the histological findings 
in experimental DC models.21,24 Although DC is accompanied 
by the formation of ulcers in the colonic mucosal epithelium , 
to the best of our knowledge, the effects of SCF have not been 
evaluated in patients or experimental models of DC. There-
fore, the objective of this study is to determine whether the 
use of SCF enemas is effective in reducing histological altera-
tions found in the colonic mucosa of an experimental model 
of DC.
Method
This study followed the recommendations of the Federal Law 
N. 11.794 and the guidelines of the Brazilian College of Animal 
Experimentation (COBEA). The research project was approved 
by the Ethics Committee on the Use of Animals in Research of 
Universidade São Francisco. 
Experimental animals
A total 36 male Wistar rats, weighing 300 to 350 g, obtained 
from the Central Animal Facility of Universidade São Fran-
cisco were used in this study. The animals were kept in indi-
vidual cages in air-conditioned environment with controlled 
temperature, light, humidity and noise level. On the eve of 
the surgical intervention, they fasted for 12 hours, except for 
water which was offered ad libitum. The cages were identified 
with the number, experimental group and subgroup to which 
they belonged and that data was tattooed with India ink on 
the tail of each animal. The rats were always fed the same 
chow, suitable for rodents, and weighed weekly.
Surgical technique
The fecal diversion in all animals was performed under gen-
eral anesthesia by intramuscular administration of 0.1 mL/100 
g of 1:1 (v / v) solution of ketamine (50 mg/mL) and xylazine 
(20 mg/mL) in the left hind leg. After being anesthetized and 
fixed to the operating table, the abdominal cavity was opened 
by making a median incision, 3 cm long. After Peyer’s patch 
identification, the distance between the patch and the loca-
tion chosen for the left colon section was measured with a 
caliper, 4 cm above the upper edge of the patch.
After ligation of the marginal arcade vessels, the colon was 
sectioned at the chosen point, externalizing the proximal seg-
ment, as the end colostomy in the left hypochondrium, fixing 
the colostomy to the skin with interrupted sutures using ab-
sorbable 4-0 monofilament thread in the four cardinal points, 
and between them. After the fixation of the proximal colos-
tomy, the caudal segment of the left colon was catheterized 
and irrigated with 40 mL of 0.9% saline solution (SS) at 37°C 
until the effluent drained through the rectum showed no fe-
cal residues.  
After the irrigation, the catheter was removed and the dis-
tal colon was exteriorized as colostomy (distal mucous fistula) 
on the lower left lateral face of the abdominal wall. The distal 
stoma was fixed with the same technique used in the proxi-
mal one. The closure of the abdominal wall was performed 
in two planes of sutures: peritoneum and aponeurosis with 
running sutures using 4-0 polyglycolic acid thread and the 
skin with 4-0 nylon thread. 
Experimental groups 
Fig. 1 shows the algorithm for the experimental group 
formation. The 36 animals were randomly divided into 
three groups with 12 rats in each. The first group received 
daily enemas containing 0.9% saline solution (control 
group). The second and third groups (experimental groups) 
received daily enemas containing SCF (EMS do Brasil Ltda., 
São Paulo, Brazil) at two different concentrations (1.0 g/kg 
and 2.0 mg/kg, respectively). In each group, six animals 
were sacrificed two weeks and the other six four weeks 
after the intervention.
Fig. 1 - Algorithm of the experimental groups formation.
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SCF (1,0g/Kg)
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Euthanization
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(n = 6)
Euthanization
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(n = 6)
Euthanization
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SCF (2,0mg/Kg)
(n = 12)
Sample collection
Two to four weeks after the intervention with the proposed 
substances, the animals were anesthetized using the same 
technique described before. The abdominal cavity was opened 
again, removing two 4-cm fragments from the colon submit-
ted or not to irrigation with the solutions at the proposed 
concentrations. The removed segments were opened longitu-
dinally from the antimesenteric border, washed with saline 
solution and divided into two 2-cm long fragments, used for 
the histological analysis. 
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Histological analysis 
The fragments removed for histological analysis were sub-
merged in a 10% formaldehyde buffered solution (Sigma, 
St. Louis, MO, USA) for 24 hours, dehydrated by exposure 
to increasing concentrations of ethanol and embedded in 
paraffin. From each paraffin block, two 5-mm thick histo-
logical sections were obtained for slide mounting. Once 
assembled, they were cleared, hydrated and stained by 
hematoxylin-eosin (HE) for the diagnosis of colitis and by 
trichrome Masson (TM) for the assessment of total collagen 
content (fibrosis). 
Slide analysis was performed under a light microscope 
(Eclipse DS-50, Nikon Inc., Osaka, Japan) by an experienced 
pathologist in IBD, blinded to the source of the material 
and the purpose of the study. Histological photographs 
were taken using a digital videosystem (DS-Fi-50, Nikon 
Inc., Osaka, Japan) previously attached to the microscope. 
The specimen analyses were always performed with a 
200x final magnification. The analysis of slides in the ir-
rigated segments was performed in sites where there were 
at least three contiguous intact colon crypts. 
The following histological parameters were considered for 
the diagnosis of DC: loss of epithelial surface (epithelial ulcer-
ations), colon crypt abscesses, inflammatory infiltrate inten-
sity and presence of epithelial fibrosis. The variables epithe-
lial loss, presence of colon crypt abscesses and inflammatory 
infiltrate were stratified as crosses, according to the degree 
of each, as follows: a) absent when there were no alterations; 
b) + when intensity was mild; c) + + moderate d) + + + intense. 
The intensity of tissue fibrosis was evaluated by the total col-
lagen content, quantified by computerized morphometry and 
stratified according to the percentage found per histological 
field studied, considering: 0, no fibrosis was identified; 1 when 
the content was ≥ 1% and ≤ 5% ; 2 when the content was > 5% 
and ≤ 10 % and finally 3 when the content was > 10%. For all 
variables analyzed, the final value considered for each animal 
was the mean value after quantification of three distinct his-
tological fields.
The morphometric analysis of collagen content was per-
formed using the imaging analysis program NIS-Elements® 
(Nikon Inc., Japan), release 3.0. The program used RGB (red, 
green, blue) system color histograms and determined the 
intensity of the chosen color (in this case blue, the color in 
which collagen is expressed when the slides are stained with 
TM) in number of pixels per selected field, transforming the 
final collagen content into percentage per field (%/field). The 
final value considered for each animal was the mean value 
obtained after reading three histological fields at the estab-
lished magnification (200x). 
Statistical analysis 
The data was described according to the median with its 
respective standard error. The comparison between groups 
was assessed by the median test and analysis of variance 
with Kruskal-Wallis test. A significance level of 5% (p <0.05) 
was used for the statistical analysis of the results, using the 
computer program Biostat® release 5.0. 
Results
Fig. 2A shows the segment obtained from colon irrigated 
with 0.9% saline for four weeks, while Fig. 2B shows the 
colon irrigated with SCF at a concentration of 2.0 g/kg/
day at the same period of time. It can be observed that in 
animals submitted to intervention with 0.9% SS there is clear 
epithelial loss, increased goblet cell population, disarray of 
the architecture and alignment of colic glands. In animals 
submitted to intervention with SCF 2.0 g/kg/day, the epithelial 
surface is preserved and the intestinal crypts are aligned, 
with normal distribution pattern and preservation of the 
goblet cell population
Fig. 2 – A, Colon segment with fecal diversion submitted 
to intervention with 0.9% saline solution for four weeks, 
where we observe the formation of epithelial ulceration, 
increase in the population of goblet cells and disarray in 
the architecture of colic glands (HE × 200). B, Colon segment 
with fecal diversion submitted to therapy with SCF (2.0 
g / kg / day) for four weeks, where we can observe the 
integrity of the colonic mucosal epithelium, maintenance 
of the goblet cell population and the cytoarchitecture of 
colic glands (HE 200 ×).
Fig. 3A shows the segment obtained from the colon 
irrigated with 0.9% saline solution for four weeks, while 
Fig. 3B shows the colon irrigated with SCF at a concentration of 
2.0 g/kg/day. In animals submitted to intervention with 0.9% 
saline solution, there is mucus accumulation inside the goblet 
cells, which have replaced part of the absorptive cells of the 
epithelial surface. One can identify the superficial epithelial 
ulcers in animals that underwent the intervention with SS. 
One can verify, through the tissue content of total collagen 
identified by TM, that animals submitted to intervention with 
0.9% SS have more fibrosis in the mucosal and submucosal 
layers when compared to animals submitted to intervention 
with SCF.  
Fig. 4 shows the values of scores found when analyzing 
the epithelial loss of colonic mucosa in the segments with 
fecal diversion of animals irrigated with 0.9% SS, SCF 1.0 g/
kg/day and 2.0 g/kg/day. It was observed that irrigation of 
the colon with fecal diversion with SCF at a concentration of 
2.0 g/kg/day preserved the mucosal epithelium, preventing 
the formation of epithelial ulcerations when compared 
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tervention in the colon with fecal diversion using a SCF con-
centration of 2.0 g/kg/day reduced the formation of abscesses 
after four weeks of irrigation, when compared to animals ir-
rigated with 0.9% SS (p = 0.02) and those irrigated with SCF 
at a concentration of 1.0 g/kg/day (p = 0.02). After four weeks 
of intervention, the reduction in abscess formation in the 
intestinal crypts was related to the SCF concentration used. 
Similarly to what occurred in relation to epithelial loss, the 
formation of colon crypt abscesses, even though related to the 
SCF concentration used, did not change with increasing time 
of intervention regardless of the SCF concentration used.
Fig. 6 shows the scores obtained when analyzing the in-
flammatory infiltrate in the mucosal and submucosal layers 
of the colon irrigated with 0.9% SS, SCF 1.0 g/kg/day and 2.0 
g/kg/day for two and four weeks. The results showed that the 
intervention on the colon with fecal diversion with SCF at a 
concentration of 2.0 g/kg/day was able to decrease the inflam-
matory infiltrate only after four weeks of irrigation, when 
compared to animals irrigated with 0.9% SS (p = 0.03). There 
was no worsening in the inflammatory infiltrate in the course 
of the intervention time, regardless of the SCF concentration 
used (p = 0.18).
Fig. 7 shows the contents of tissue collagen found in the 
mucosal and submucosal layers of the colon wall in segments 
irrigated with 0.9% SS, SCF 1.0 g/kg/day and 2.0 g/kg/day for 
two and four weeks of intervention. It was observed that ir-
rigation of the colon with fecal diversion with SCF at a con-
centration of 2.0 g / kg / day for four weeks was able to reduce 
the total tissue collagen content when compared to animals 
treated with daily irrigation with SS 0.9% and SCF at a con-
centration of 1.0 g/kg (p = 0.009). The presence of fibrosis, al-
beit reduced with higher concentrations of the drug, did not 
change with increasing duration of intervention time, regard-
less of the SCF concentration used.
Fig. 3 – A, Colon segment with fecal diversion submitted to 
therapy with 0.9% saline solution for four weeks, where we 
observe the intense deposition of collagen in the mucosal 
and submucosal layers of the colon wall (TM 200 ×). B, 
Colon segment with fecal diversion submitted to therapy 
with SCF (2.0 g / kg / day) for four weeks, which shows 
that there was less collagen deposition when compared to 
animals irrigated with 0.9% saline solution (TM 200×).
Fig. 4 – Epithelial loss comparing animals submitted to 
daily irrigation with 0.9% saline solution (SS), sucralfate  
1.0 g / kg and 2.0 g / kg after two and four weeks  
of intervention. Mann-Whitney test. a = p < 0.05  
(SCF 2.0 g / kg vs. 0.9% saline solution).
to animals irrigated with 0.9% SS (p = 0.03). The mucosal 
epithelium of the animals irrigated with SCF was regular and 
had a smaller population of goblet cells. In animals irrigated 
with SCF it was observed an increased amount of mucus 
covering the epithelial surface, when compared to control 
animals. When assessing the level of epithelial loss with 
increasing duration of intervention, although it is related to 
the concentration used, it was observed that it did not worsen 
with increasing duration of intervention time, regardless of 
the concentration of SCF used. 
Fig. 5 shows the scores obtained by analyzing the presence 
of crypt abscesses in the segments irrigated with 0.9% SS, SCF 
1.0 g/kg/day and 2.0 g/kg/day. The results show that the in-
Fig. 5 – Presence of abscesses in crypts comparing with 
animals treated with daily irrigation with 0.9% saline 
solution (SS), 1.0 g SCF / kg and 2.0 g / kg after two and four 
weeks of intervention. Mann-Whitney Test. a e b = p < 0,05  
(a = SCF 2.0 g/kg vs. SS 0.95; b = SCF 2.0 g/kg vs. SCF 1.0 g/kg).
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Fig. 6 – Inflammatory infiltrate in animals subjected to 
daily irrigation with 0.9% SS, SCF 1.0 g/kg and 2.0 g/kg after 
two and four weeks of intervention. Mann-Whitney Test.  
a = p < 0.05 (a = SCF 2.0 g/kg vs. SS 0.95).
Fig. 7 – Content of tissue collagen in animals submitted to 
daily irrigation with 0.9% SS, SCF 1.0 g / kg and 2.0 g / kg 
after two and four weeks of intervention. Mann-Whitney 
Test. a e b = p < 0.01 (a = SCF 2.0 g/kg vs. SS 0.95;  
b = SCF 2.0 g/kg vs. SCF 1.0 g/kg).
Discussion
DC is an inflammatory disease that affects the large intestine 
segments with fecal diversion.25 Endoscopic examination of 
the colon or rectum with fecal diversion shows endoscopic 
alterations that are characteristic of the disease in all patients 
after a period of time ranging from three to 36 months the 
diversion.25 The endoscopic appearance of the intestinal mu-
cosa may vary depending on the intensity and duration of the 
disease and common findings are: the absence of the vascu-
lar pattern of the submucosal layer due to the inflammatory 
infiltrate, frailty in the excluded mucosa caused by greater 
vascular congestion, formation of superficial ulcerations that 
determine spontaneous bleeding or at minimal local trauma 
and stiffness of the intestinal wall by greater deposition of 
collagen, leading to fibrosis of the colon wall.26 
In more severe cases there may be formation of larger aph-
thous ulcers, making it difficult to make the differential di-
agnosis with other forms of IBD, particularly URC.27 The pres-
ence of ulcerations on the mucosal surface and the intense 
inflammatory process are the most significant alterations, as 
they are directly related to the main symptoms of the disease 
- presence of blood and mucus in stools - reported by most 
patients. Thus, when establishing therapeutic strategies for 
the treatment of DC, these aspects should be considered. 
The physiopathological bases for the development of DC 
are not yet fully understood.28 However, most authors believe 
that the etiopathogenesis of DC is related to a deficiency in 
the supply of SCFA to the colonic mucosa.29 This possibility 
is supported by the results of studies showing that the defi-
ciency in the supply of SCFA to the cells of the colonic mucosa 
is related to the development of DC, while the restoration of 
fecal stream or irrigation of the excluded segments with SCFA 
improves symptoms and reverts endoscopic and histological 
changes found in the disease.30 
Despite the important role played by the maintenance of 
SCFA supply to prevent the development of DC, the molecu-
lar mechanisms that cause epithelial lesions have been un-
derstood only recently.20 Experimental studies have shown 
that epithelial lesion found in DC models are related to tissue 
oxidative stress due to an increased production of ROS by the 
colonic mucosa, a site known to be deficient in antioxidant 
enzyme systems.31,32 It is well established that ROS such as 
superoxide (O2.), hydroxyl (OH), hydrogen peroxide (H2O2) and 
hypochlorous acid (HClO) are produced in excess by the co-
lonic mucosa devoid of fecal stream and are harmful to it.33 
ROS are capable of damaging the different defense systems 
of the colonic mucosa that prevent the migration of antigens 
and bacteria present in the intestinal lumen to the proximity 
of the sterile layers of the colon wall.20,22,23,25 The possibility 
that deficiencies in the supply of SCFA may trigger the onset 
of DC gained more support after studies demonstrated that 
substances that inhibit E-oxidation of SCFA in the intestinal 
lumen are able to trigger the onset of DC, whereas the use of 
enemas in the colon without fecal stream with antioxidants, 
such as 5-ASA and n-acetylcysteine have been successfully 
used for the treatment of the disease.21,24,34 
SCF is a cytoprotective agent that has been used for more 
than three decades in the treatment of duodenal peptic ul-
cers, stress ulcers and GERD. The substance is a sucrose and 
sulfate-aluminum complex which, when in contact with hy-
drochloric acid in the stomach, forms a viscous gel that ad-
heres to the gastric mucosa creating a physical barrier that 
protects the mucosa and prevents the diffusion of hydrochlo-
ric acid into the gastric wall. The complex formed, in addition 
to preventing the degradation of the mucus that covers the 
gastrointestinal epithelium, stimulates the production of bi-
carbonate, acting as a buffer with cytoprotective properties. 
When in contact with the raw surface of epithelial lesions of 
the digestive tract mucosa, SCF adheres tightly to proteins 
on the surface of ulcerations, mainly albumin and fibrino-
gen, thus forming a stable and insoluble complex, creating a 
protective layer that covers and protects the ulceration. Re-
cent studies have shown that SCF stimulates the production 
of prostaglandin E2 (PGE2), epithelial growth factor (EGF) and 
gastric mucus.10,35
It has been previously shown that the PGE-2 is the primary 
product of arachidonic acid metabolism, playing a critical role 
in maintaining the integrity of the gastrointestinal epitheli-
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um.36 The increase in PGE-2 production, the main metabolite 
of COX-1 and COX-2, can regulate the angiogenesis, motility 
and survival of epithelial and endothelial cells. A number of 
studies have shown that SCF increases the production of PGE-
2 and prostaglandin-F1 by cells and that this effect is dose-
dependent.37 
Louw et al. have shown that SCF also significantly increas-
es the production of TGF-D and that the combination of SCF 
and TGF-D is able to induce the proliferation of mucosal cells 
and increase local blood supply, favoring the healing process.38 
The inflammatory aggression that develops after tissue 
damage is often involved in the induction of cell apoptosis, 
which is considered the main reason for decreased cellularity 
during the different stages of wound healing. SCF can inhibit 
cell apoptosis after tissue damage. Matsuu-Matsuyama et al. 
demonstrated that SCF protects the distal colonic epithelium 
of rats submitted to radiotherapy, by reducing the level of cell 
apoptosis by inhibiting the activation of caspase-3 and that 
this phenomenon may be dependent on p53 protein pathway 
due to its capacity to decrease, along with p21 protein expres-
sion, the Bax/Bcl2 ratio in the colon cells.14
With better knowledge of SCF mechanisms of action, it 
was observed that in addition to working as a mechanical 
barrier, it is also able to preserve vascular integrity, increase 
mucus secretion and EGF production, responsible for stimu-
lating epithelial regeneration, angiogenesis and epithelializa-
tion, considered the main phase of cutaneous-mucous wound 
healing. The formation of a stable complex, firmly adhered to 
ulcers of the digestive tract, maintains EGF production for a 
long period of time, by exerting a continuous trophic stimu-
lation on the gastrointestinal mucosa. This property protects 
the lining of the digestive tract from new aggressions, as well 
as stimulates the migration and proliferation of cells from 
germinal regions of the intestinal crypts.39 
Studies have shown that SCF also has a bactericidal effect, 
effective against Escherichia coli, Pseudomonas aeruginosa and 
Staphylococcus aureus. It has been shown that reducing the 
bacterial population surgical wounds located in the intestinal 
lumen is an important aspect of the healing process.40 
Recently it was shown that the use of high concentrations of 
SCF decreases the production of ROS by leukocytes or by the 
xanthine-xanthine oxidase system after cell injury induced 
by H2O2, showing that the substance has antioxidant activity.
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Fig. 8 shows a summarized version of the known mech-
anisms of action of how the SCF molecule acts at different 
stages of the healing process in surgical wounds.
All these SCF properties combined with the etiopathogenic 
mechanisms of DC make interesting the assessment of the 
topical effects of the substance in experimental models of DC. 
However, as far as we know, this possibility has not yet been 
studied. The results of the present study confirm the benefi-
cial effects of the use of enemas with SCF in the prevention 
of the most frequently found histological alterations in DC. 
We found that the topical application of SCF in the proposed 
model reduced epithelial loss, mainly when the substance is 
applied at a higher concentration and for a longer period of 
time.
In the animals from the group where intervention was 
performed with 0.9% SS, the epithelial surface was irregular, 
with a “brush border” aspect, and in some areas we observed 
the formation of small (Fig. 2A) or larger ulcers (Fig. 3A). In 
all animals treated with SCF, regardless of the concentration 
used, there was the formation of a gelatinous layer on the 
colonic mucosa that preserved the epithelial surface, without 
epithelial ulcerations (Figs. 2B and 3B).
These findings seem to confirm the substance’s cytopro-
tective and regenerative properties of the mucosal epitheli-
um. Likewise, it was observed that in animals submitted to 
intervention with SCF, there was a greater amount of mucus 
covering the epithelial surface and that the goblet cells did 
not have their cytoplasm filled with mucus as happened in 
animals submitted to irrigation with 0.9% SS (Fig. 2A, B).
Fig. 8 – Molecular mechanisms of action of SCF on 
epithelial healing. A, Release of growth factors involved 
in epithelial wound healing. B, SCF increases the 
bioavailability of growth factors and prostaglandins and 
decreases the production of ROS, enhancing angiogenesis, 
granulation and tissue re-epithelialization. EGF, epidermal 
growth factor; EGFr epidermal growth factor receptor; 
ROS, reactive oxygen species; ECM , extracellular matrix; 
PDGF, platelet-derived growth factor; TGF-E, transforming 
growth factor E; KGF, keratinocyte growth factor ; FGF2 , 
fibroblast growth factor 2 ; TGF-D , transforming growth 
factor D ; PDGF BB , platelet-derived growth factor , FGF , 
fibroblast growth factor; VEGF, vascular endothelial growth 
factor; IGF, insulin-like growth factor; PG , prostaglandin ; 
PLT , platelets, PMN, polymorphonuclear leukocytes; Mø, 
macrophages, SUC: sucralfate. (Modified from Masuelli  
et al. , 201010.)
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The epithelial surface integrity in animals submitted to 
intervention with SCF may also be related to the capacity 
of the substance to increase the local levels of PGE-2, TGF-D, 
EGF and FGF, all of which, besides exerting a trophic effect on 
the intestinal epithelium, accelerate the healing process by 
stimulating cell proliferation and migration.11,36 The improve-
ment in epithelial regeneration in the present study showed 
to be dose-dependent. One possible explanation for this fact 
is the greater capacity of mechanical protection when using 
a higher concentration as well as the increased production of 
PGE-2, TGF-D, EGF and FGF, which is also dose-dependent.36
The animals submitted to irrigation with higher SCF con-
centrations and for a longer period of time had lower rates of 
abscess formation in crypts and less inflammatory infiltrate 
(Fig. 4). It is possible that this finding may be related to agrea-
ter protection of the epithelial surface provided by the gelati-
nous layer that forms on the intestinal mucosa, as well as the 
increased amount of mucus on the site.
The formation of this additional protective layer can hin-
der the migration of antigens and bacteria from the intestinal 
lumen into the sterile layers of the colon wall, decreasing the 
local inflammatory response. The lower inflammatory infil-
trate, as well as the lower formation of cryptic abscesses may 
also be related to the bactericidal activities of the substance. 
It must be also recalled that SCF has an antioxidant activ-
ity, neutralizing ROS formed by epithelial cells with energy 
metabolism altered by a deficiency in the supply of SCFA due 
to the absence of fecal stream. The neutralization of these 
ROS can decrease levels of oxidative stress on site, making 
it difficult for these radicals to attack the epithelial surface 
cells. At the moment we are measuring in these same ani-
mals, the tissue levels of ROS by assessing lipid peroxidation 
of membranes (tissue levels of malondialdehyde) and of oxida-
tive stress to cell DNA (8-OHdG by immunohistochemistry), in 
order to confirm the importance of the antioxidant activity of 
SCF in the prevention of oxidative tissue damage found in DC . 
When analyzing the presence of tissue fibrosis comparing 
animals preventively irrigated with SCF or 0.9% SS, we found 
that the use of enemas with SCF at higher concentrations sig-
nificantly reduced the content of collagen tissue, suggesting 
the presence of less local fibrosis. It is possible that this ef-
fect is related to a lower local inflammatory process result-
ing from mechanical protection given by the substance by 
reducing bacterial infiltration and inflammation resulting 
from antioxidant and antibacterial activities. By modulating 
the production and release of pro-inflammatory cytokines, 
stimulating the production of PGE-2 and EGF, it is possible 
that collagen deposition, as well as epithelial replacement, 
are carried out in a more harmonic way when compared to 
the animals irrigated with 0.9% SS.
As described by other authors, the protective layer on the 
epithelium formed by the SCF causes the release of EGF and 
FGF on site for a longer period of time which improves the 
healing of epithelial injury.2,11,41 The increased activity of FGF 
seems to be a major mechanism of action of SCF.11,42 FGFs are a 
class of heparin-binding proteins, mainly represented by basic 
FGF (bFGF) and acidic FGF (FGF), which stimulate mitogenic, 
chemotactic and angiogenesis activity in many cell types, 
including mesenchymal and neural epithelial cells.11 Because 
of their myogenic activity on endothelial cells, chondrocytes 
and fibroblasts, FGFs play a key role in all stages of wound 
healing. It is possible that greater stimulation to EGF and FGF 
production can modulate tissue epithelialization, decreasing 
collagen deposition as it occurs in animals irrigated with 
0.9% SS 
The results of this study suggest that the properties of the 
SCF molecule of improving the mechanical barrier function 
and accelerating wound healing by stimulating the produc-
tion of growth factors, especially FGF, can improve the heal-
ing of the colonic mucosa without fecal stream. Moreover, the 
induction of prostaglandin production, as well as protection 
against apoptosis, promoting tissue re-epithelialization, can 
improve the healing process of the colonic mucosa. These 
biological properties have encouraged the clinical use of the 
substance as a topical agent for the treatment of different 
types of colitis caused by inflammation, infection and physi-
cal damage, such as in URC and actinic rectitis. According to 
the clinical evidence reported in the literature, it seems that 
SCF promotes healing of the intestinal mucosal epithelium in 
these patients. 
The results of this study suggest that for all its properties, 
topical application of SCF can also be a valid strategy for the 
prevention and treatment of DC. However, clinical studies in 
humans, with a significant number of cases are still necessary 
to validate the experimental results found in this study. 
Conclusion
Considering the conditions of this study, topical application 
of enemas containing SCF improves epithelial changes found 
in experimental DC.
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